Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.64 |
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | POLB | P06746 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19900671 | 0.89 | KMT2A (0.78) | KMT2ARAB9ANPC1POLBMEN1 | |
| SCHEMBL1260494 | 0.78 | KMT2A (0.64) | KMT2ARAB9ANPC1POLBMEN1 | |
| SCHEMBL2682787 | 0.78 | KMT2A (1.00) | KMT2ARAB9ANPC1POLBMEN1 | |
| SCHEMBL28576782 | 0.78 | RAB9A (0.64) | KMT2ARAB9ANPC1POLBMEN1 | |
| SCHEMBL28615396 | 0.78 | KMT2A (0.64) | KMT2ARAB9ANPC1POLBMEN1 | |
| SCHEMBL118567 | 0.78 | KMT2A (0.64) | KMT2ARAB9ANPC1POLBMEN1 | |
| SCHEMBL6153838 | 0.78 | KMT2A (1.00) | KMT2ARAB9ANPC1POLBMEN1 | |
| SCHEMBL6468984 | 0.78 | RAB9A (0.64) | KMT2ARAB9ANPC1POLBMEN1 | |
| SCHEMBL558024 | 0.78 | KMT2A (0.64) | KMT2ARAB9ANPC1POLBMEN1 | |
| SCHEMBL95792 | 0.78 | KMT2A (0.58) | KMT2ARAB9ANPC1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109503686-B | Novel nucleoside phosphoramidate compounds and uses thereof | 南京圣和药业股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-108314697-B | Novel nucleoside phosphoramidate compounds and uses thereof | 南京圣和药业股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| CN-108546277-B | Novel nucleoside phosphoramidate compounds and uses thereof | 南京圣和药业股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-9963480-B2 | Nucleoside phosphoramidate compound and use thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2018-05-08 | — | — | US | disclosed |
| US-20150361123-A1 | NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD (CN) | 2015-12-17 | — | — | US | disclosed |
| EP-2940031-A1 | NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2015-11-04 | — | — | EP | disclosed |
| US-8933083-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| CN-104031104-A | Novel nucleoside phosphoramidate compounds and uses thereof | NANJING SANHOME PHARMACEUTICAL CO LTD | 2014-09-10 | — | — | CN | disclosed |
| US-20130023527-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-8293751-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| WO-2003086385-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-1326861-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-6566377-B2 | β3 adrenergic receptor agonists and uses thereof | PFIZER INC. | 2003-05-20 | — | — | US | disclosed |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | DAY ROBERT F (US) | 2002-05-02 | — | — | US | disclosed |
| WO-2002032897-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
| US-4582906-A | REDUCED SOIL BIODEGRADATION OF THIOL CARBAMATES | STAUFFER CHEMICAL COMPANY (US) | 1986-04-15 | — | — | US | disclosed |
| US-4540429-A | 4-Phenyl-1,2,3-thiadiazoles as herbicide extenders | STAUFFER CHEMICAL COMPANY (US) | 1985-09-10 | — | — | US | disclosed |
| EP-0062773-B1 | 4-Phenyl-1,2,3-thiadiazoles as herbicide extenders | STAUFFER CHEMICAL COMPANY (US) | 1984-12-05 | — | — | EP | disclosed |
| EP-0062773-A1 | 4-Phenyl-1,2,3-thiadiazoles as herbicide extenders | STAUFFER CHEMICAL COMPANY (US) | 1982-10-20 | — | — | EP | disclosed |
| US-3940407-A | β-Adrenergic blocking agents in the 1,2,3-thiadiazole series | SYNTEX (U.S.A.) INC. (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023527-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | CYP7A1, GPR119, UGT1A1 | KMT2A 1969/4885RAB9A 2866/4885NPC1 427/4885 |
| US-20150361123-A1 | NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF | PNP, NUDT1, SLC28A1 | KMT2A 3538/4885RAB9A 1559/4885NPC1 346/4885 |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | ADRB3, ADRA1A, ADRB1 | KMT2A 3066/4885RAB9A 1019/4885NPC1 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.